Toll-like receptors ligand immunomodulators for the treatment congenital diaphragmatic hernia
Our research has shown that TLR ligand immunomodulators that influence anti-inflammatory macrophage activation can be effective in treating CDH, being nontoxic for the mothers or pups suggesting that those TLR ligands are a promising solution for CDH leading to orphan drug designation for CS1. The immune system of the fetus would be responsible for repairing the damage and closure of the hernia in the diaphragm and enhanced proper lung development after CS1 treatment.
Authors
- Javier Merino (ORCID: https://orcid.org/0000-0003-3397-8171)
- Beatriz Salvador (ORCID: https://orcid.org/0000-0002-2425-6479)
- Rita Carmona (ORCID: https://orcid.org/0000-0002-9686-473X)
- Ramón Muñoz‐Chápuli (ORCID: https://orcid.org/0000-0001-6392-6802)
- Miguel Ángel Llamas (ORCID: https://orcid.org/0000-0002-0075-9020)
- L Martínez (ORCID: https://orcid.org/0000-0001-8844-4893)
- Manuel Fresno (ORCID: https://orcid.org/0000-0002-9223-5477)
- Juan Antonio Tovar
- Mayte Vallejo‐Cremades
- Laura Córdoba
Institutions
- Hospital La Paz Institute for Health Research (ES)
- Centro de Biología Molecular Severo Ochoa (ES)
- Universidad Autónoma de Madrid (ES)
- Universidad de Málaga (ES)
Publication Details
- Journal
- Orphanet Journal of Rare Diseases
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1186/s13023-024-03384-7
- Primary Topic
- Congenital Diaphragmatic Hernia Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fundación Banco Santander
- Fundación Ramón Areces
- Comunidad de Madrid
- Ministerio de Ciencia e Innovación